S8 E3: Top 3 Pain Points for Pharma's Partners

Deciding whether something is promotional sounds easy? We put three common assumptions to the test:Does mentioning the brand name automatically make it promotional?If prescribing information is included, does that make it promotional?If a rep discusses it, is it always promotional?The answers may not be what you expect. Whether you work in commercial, medical, compliance or at an agency, this 4-minute episode will sharpen how you approach one of the most fundamental questions under the ABPI Code.

New agencies bring fresh thinking and ideas pharma teams love to see. But some of the most exciting pitches can create compliance problems from the start.In this podcast, we discuss innovative concepts and cover how agencies can build compliance into the creative process whilst pharma should ensure agency competency and whose responsibility is it anyway...?!Essential listening for agency teams new to pharma and for the industry colleagues who brief them. Come to conference!

Rina & Jean discuss where Case/0685/08/25 the PMCPA talked about what Lilly should have known was foreseeable. Does this mean we all go out and but crystal balls?

Event organisers, publishers and agencies work with lots of pharma companies, and they tell us the same things again and again. Rina & Jean share the top 3 issues. Hear more at our conference on how pharma and third parties can navigate compliance together (& make life easier for everyone).

We look at what went wrong, how doctors.net has tightened things up since, and what we'd have suggested. If your brand, med comms or agency team uses third-party media publishers, this one's for you. The lesson is that outsourcing the channel doesn't outsource the responsibility! Cases: 0748/09/25, 0832-0838/12/25

Grab a biccie & cuppa as we gossip about the GSK campaign complaints (Cases: 0269, 0568 & 0874) .... genuine gasps from Rina when Jean explains how the "courtesy copy" bit them in the bum

It's faster, and done right, good for everyone at the table. So why does the PMCPA's Abridged Procedure remain the road less travelled? Rina & Jean investigate the case for using it more: the benefits for companies facing complaints, for complainants seeking resolution, and for the PMCPA itself. If it works this well, what's holding the PMCPA back?

The PMCPA has released its 2025 Annual Report - but does the data point to a genuinely transformational year, or business as usual? In this episode, Rina & Jean dig into the numbers to ask the question everyone in pharma is thinking: are companies actually getting more compliant, or are complaints simply getting worse?

Whether you are a new or seasoned signatory, the question of signatory standards is worth considering. Two experienced signatories (Rina & Jean) chat about 3 of the most important standards (the full 10 will be discussed in detail at our subscribers webinar on 17 Sept 26 - get in touch at [email protected] if you are not a subscriber).

Why does this matter to you? Because for the first time 'it happened ages ago' is now a legitimate defence (within limits). PMCPA Q&A on policy here.